JEDDAH — AbbVie, a global biopharmaceutical company, supported an event of the Disabled Children's Association in recognition of the annual World Disability Day. The occasion was held under the patronage of Prince Sultan Bin Naser Bin Abdulaziz in Jeddah last December 4-5. The event included a number of activities and programs for children under the theme of “Sustainable development - the promise of technology”. AbbVie's support for such programs aims to highlight the strong potentials of the children with disabilities and address their needs. Rami Fayed, General Manager of AbbVie in Saudi Arabia, explains: “Making a remarkable impact on people's lives is in the heart of what we do at AbbVie. Supporting the activities of the World Disability Day is part of our global CSR program ‘Week of Possibilities' where we take part in various social activities and engage our team with volunteering opportunities that positively impact people's lives”. Dr. Zuhair A. Maimini, Director of the King Abdullah Bin Abdul Aziz Center in Jeddah. commented: “We are working hard to spread awareness about the potential of the disabled children while helping them reach their potential and identify their role in the community. AbbVie has set a good example with their swift response to participate in this event and support us with volunteers” The activities of the World Disability Day, organized by the Disabled Children's Association, were full of fun and excitement while focusing on the educational side as well. With a rich, 125-year heritage of developing pharmaceuticals, AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. A global enterprise that serves patients in 170 countries, AbbVie launches in the Kingdom of Saudi Arabia with a strong commitment to the country's healthcare, where it has been operating as Abbott for around 55 years. AbbVie provides a broad portfolio of market leading medicines for the treatment of some of the world's most complex and serious diseases. The portfolio includes the world's number one biologic and as well as other leading therapies in Neonatology, Anesthesia, Rheumatology, Gastroenterology, Dermatology, Neurology, Virology, oncology and nephrology. AbbVie's long-term growth will be fueled by a compelling pipeline – with more than 10 compounds in late stage clinical trials or registration – as well as new discoveries to address diseases including Hepatitis C, Alzheimer's disease, Parkinson's disease, multiple myeloma and endometriosis. — SG
